Conference spotlight and mixed analyst views put Madrigal Pharmaceuticals (MDGL) in focus

Madrigal Pharmaceuticals (MDGL) is back on investors’ radar after recent analyst commentary on its MASH treatment Rezdiffra and plans to showcase fresh clinical and real world data at the upcoming EASL Congress 2026.

The stock is also drawing attention ahead of Madrigal’s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, where management is expected to discuss Rezdiffra and the company’s broader MASH-focused pipeline.

The recent mix of cautious and upbeat analyst commentary around Rezdiffra coincides with a share price that has slipped 8.2% over the past month and 19.0% year to date. However, Madrigal’s 1 year total shareholder return of 62.7% and 5 year total shareholder return of about 3.6x suggest longer term holders have still seen strong gains. This hints that sentiment is being reset rather than completely reversed ahead of key 2026 data events.

If Rezdiffra and liver focused treatments are on your radar, this can be a good moment to widen the search and look at 40 healthcare AI stocks as another way to spot potential opportunities in healthcare.

With Madrigal shares down 19.0% year to date but still up 62.7% over 12 months and trading at a discount to recent analyst targets, is this resetting sentiment creating a potential entry window, or is anticipated growth already reflected in the price?

Most Popular Narrative: 28.4% Undervalued

The most followed narrative currently pegs Madrigal’s fair value at $671.07 per share versus a last close of $480.77, framing the stock as materially undervalued based on detailed cash flow and earnings assumptions.

The analyst price target for Madrigal Pharmaceuticals has been revised higher to $671.07, up from $603.47. Analysts now factor in updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E, following recent research that highlights both enthusiasm for Rezdiffra's commercial potential and some valuation concerns.

Curious what justifies a fair value well above the current share price? The narrative leans on rapid revenue build, sharply improving margins and a richer future earnings multiple. Want to see how those moving parts combine into that $671.07 figure?

Result: Fair Value of $671.07 (UNDERVALUED)

However, this hinges on Rezdiffra staying on track and on competitors, including GLP 1 therapies, not squeezing long term pricing or market share harder than expected.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment clearly split, it makes sense to look at the numbers yourself, act while the market is still rethinking the story, and assess the 3 key rewards.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop with a single stock. Broaden your watchlist using focused screeners that surface specific strengths.

• Target potential mispricings by scanning companies that currently screen as 44 high quality undervalued stocks and see which ones fit your own thesis.
• Prioritise resilience by reviewing 71 resilient stocks with low risk scores and concentrating on stocks that align with your tolerance for volatility.
• Hunt for less crowded ideas by checking the screener containing 20 high quality undiscovered gems before the wider market pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.